8-K: BioNexus Gene Lab Forms Strategic Alliance with Fidelion for VitaGuard MRD

BioNexus Gene Lab Corp. has entered into definitive agreements with Fidelion Diagnostics to commercialize the VitaGuard minimal-residual-disease platform in Southeast Asia through a cross-equity strategic alliance.

Summary

• BioNexus Gene Lab Corp. (BGLC) entered into a definitive Share Subscription and Shareholders Agreement (SSSA) with Fidelion Diagnostics Pte. Ltd. (Fidelion) and other parties on November 12, 2025.
• This agreement establishes a partnership framework for Fidelion's VitaGuard minimal-residual-disease (MRD) platform.
• BGLC will subscribe for newly issued ordinary shares of Fidelion, resulting in BGLC holding at least 15.0% of Fidelion's enlarged share capital.
• In exchange, BGLC will issue to Fidelion restricted shares representing 19.9% of BGLC's outstanding common stock (pre-issuance).
• The transaction aims to support the development and commercialization of MRD testing in Southeast Asia, with BGLC gaining exclusive commercialization rights in the ASEAN region.
• Completion is subject to conditions precedent, including the execution of a Southeast Asia intellectual property license between BGLC and Fidelion.
• The targeted post-closing fully diluted capitalization for Fidelion acknowledges Tongshu Biotechnology (Hong Kong) Co., Limited holding approximately 30% and BGLC approximately 15%.

Sentiment

Score: 8

Explanation: The filing announces a significant strategic alliance and cross-equity partnership that could unlock substantial growth opportunities for BGLC in the high-growth Southeast Asian diagnostics market. The technology (VitaGuard) appears promising, and the partnership structure aligns key stakeholders. However, the transaction is still subject to conditions precedent and further agreements, introducing some execution risk.

Positives

• Secures exclusive commercialization rights for Fidelion's VitaGuard MRD platform in the Southeast Asia (SEA) region for BGLC.
• VitaGuard platform offers high-fidelity, tumor-naive liquid biopsy for MRD detection, with clinical impact shown by detecting ctDNA down to 0.02% variant allele frequency at ~20,000 depth, recovering ~95% cfDNA.
• The tumor-naive design eliminates the need for a tissue sample, potentially broadening access to MRD testing.
• The cross-equity alignment fosters a strong strategic partnership between BGLC, Fidelion, and Tongshu, aligning ownership and governance for rapid regional rollout.
• Aims to significantly reduce the cost of MRD testing, similar to how the "$1,000 genome" democratized sequencing.
• BGLC is expected to lead regulatory submissions and commercialization efforts in SEA, initially focusing on Singapore and Malaysia.
• The collaboration contemplates data-driven product development and potential companion-diagnostic programs, building longitudinal datasets for future AI applications.

Negatives

• The issuance of restricted shares representing 19.9% of BGLC's outstanding common stock to Fidelion will result in dilution for existing BGLC shareholders.
• The completion of the SSSA is subject to specified conditions precedent, including the execution of an exclusive intellectual property license for Southeast Asia, which have not yet been executed.
• There is no assurance that the remaining agreements will be entered into on favorable terms, or at all, or that the conditions precedent will be satisfied.

Risks

• Failure to timely negotiate, execute, or close one or more contemplated agreements, or to satisfy conditions precedent.
• Delays or negative determinations in regulatory submissions or approvals in ASEAN markets.
• Challenges in transferring, protecting, or enforcing intellectual property, or in maintaining third-party rights.
• Manufacturing, quality, or supply-chain constraints.
• Slower-than-expected clinical adoption, pricing, or reimbursement for the VitaGuard platform.
• Dependence on counterparties (Fidelion, Tongshu) and third-party service providers.
• Competition and technological change in the liquid biopsy and MRD testing market.
• Macroeconomic, geopolitical, or public-health developments impacting operations.
• Compliance with stock-exchange, securities, and other regulatory requirements.
• Risks related to governance, potential conflicts of interest, and related-person approvals, including with respect to any concurrent service by a Company executive at Fidelion and any inducement or incentive arrangements.
• Any requirement to obtain shareholder approval under applicable stock-exchange rules.

Future Outlook

The parties expect completion of the definitive agreements following satisfaction of remaining conditions precedent within the specified period. BGLC anticipates leading regulatory submissions and commercialization efforts for the VitaGuard platform in Southeast Asia, with an initial focus on Singapore and Malaysia, aiming to expand access to tumor-naive MRD testing in routine care and build longitudinal datasets for future AI and companion-diagnostic programs.

Management Comments

• "Moving from agreements to execution marks the next growth chapter for BGLC. The sub-$1,000 genome changed medicine by collapsing cost without losing quality. We intend to do the same for MRD – bringing high-fidelity, tumor-nave blood tests to everyday care across ASEAN." Sam Tan, CEO of BGLC and Fidelion.
• "These agreements align our teams to advance high-fidelity, tumor-nave MRD testing across Southeast Asia as we work through initial regulatory pathways and commercial preparation." Sam Tan, CEO of BGLC and Fidelion.
• "VitaGuard was engineered to work in the real-world. By uniting Tongshu’s research, Fidelion’s product development, and BGLC’s planned Southeast Asia commercialization, we aim to expand access to tumor-nave MRD testing in routine care." Dr. Yan Linghua, CEO of Tongshu Gene and Director of Fidelion.

Industry Context

The announcement positions the VitaGuard platform within the rapidly evolving field of liquid biopsy and minimal residual disease (MRD) testing in oncology. It draws a parallel to the "sub-$1,000 genome" revolution, suggesting a similar disruptive potential for cost reduction and accessibility in MRD testing. The focus on Southeast Asia highlights a strategic move into a growing regional market for advanced diagnostics. The tumor-naive design addresses a key limitation of traditional MRD tests, potentially broadening its applicability.

Comparison to Industry Standards

• The filing explicitly compares the intended impact of VitaGuard to the "sub-$1,000 genome" which "unlocked mainstream sequencing" and "democratized sequencing." This sets a benchmark for collapsing costs and increasing access in the MRD testing space.
• The ambition is to achieve a similar transformative effect on MRD testing as the "$1,000 genome" did for genetic sequencing, by bringing high-fidelity, tumor-naive blood tests to everyday care across ASEAN.

Management Changes

Corporate Governance

Related Party Transactions

• Mr. Su-Leng Tan Lee, CEO and director of BioNexus Gene Lab Corp., beneficially owns approximately 4.1% of Fidelion as of November 11, 2025.
• Mr. Tan Lee is expected to serve concurrently as Chief Executive Officer of Fidelion as part of the transaction framework, with no agreement for further compensation for this role as of the report date.
• These transactions were reviewed and approved in accordance with BGLC's Related Person Transactions Policy by the independent and disinterested members of BGLC's Board, with Mr. Tan Lee abstaining from the vote.

Stakeholder Impact

• Shareholders (BGLC): Potential for long-term growth and market expansion in Southeast Asia through exclusive commercialization rights for a promising diagnostic platform. However, existing shareholders will experience dilution from the issuance of 19.9% of BGLC's common stock to Fidelion.
• Shareholders (Fidelion/Tongshu): Gain BGLC equity and strategic partnership for commercialization, leveraging BGLC's regional expertise.
• Customers/Patients in Southeast Asia: Expected to gain broader and more affordable access to high-fidelity, tumor-naive Minimal Residual Disease (MRD) testing, potentially leading to earlier cancer recurrence detection.
• Employees (Fidelion): The Company intends to establish a board-approved equity incentive plan (EIP) to incentivize key employees, directors, and consultants.

Next Steps

• Satisfaction of remaining conditions precedent for the SSSA completion, including the execution of an exclusive intellectual property license for Southeast Asia between BGLC and Fidelion.
• Negotiation, execution, and closing of companion agreements between Fidelion and Wuxi Tongshu Biotechnology Co., Limited relating to intellectual property ownership and patent-support services.
• BGLC to lead regulatory submissions and commercialization efforts for VitaGuard in Southeast Asia, with an initial focus on Singapore and Malaysia.
• Establishment of a board-approved equity incentive plan (EIP) for Fidelion.
• Potential data-driven product development and companion-diagnostic programs, building longitudinal datasets for future AI applications.

Key Dates

Recommendation

The definitive agreement for a strategic alliance with Fidelion Diagnostics to commercialize the VitaGuard MRD platform in Southeast Asia represents a significant strategic move for BioNexus Gene Lab Corp. This partnership offers substantial long-term growth potential in a critical and expanding diagnostic market. The cross-equity structure aligns interests, and the technology itself appears promising with its tumor-naive design and high fidelity. However, the transaction involves dilution for existing BGLC shareholders and is still subject to several conditions precedent, including the execution of key intellectual property agreements. There are also inherent risks associated with regulatory approvals, market adoption, and execution in a new region. Given these factors, a "hold" recommendation is appropriate for investors to monitor the successful satisfaction of conditions, the execution of the commercialization strategy, and the initial market reception of the VitaGuard platform before making further investment decisions.

Keywords

BioNexus Gene Lab Corp., BGLC, Fidelion Diagnostics, VitaGuard, Minimal Residual Disease, MRD, Liquid Biopsy, Southeast Asia, ASEAN, Strategic Alliance, Equity Investment, Commercialization, Oncology, Diagnostics, Biotechnology, Tongshu Biotechnology